Abstract
Only a minority of studies addressing the association between immune-related adverse events (IrAE) and outcome considered the immortaltime bias, with conflicting results. PubMed, Embase, Web of Science and Scopus were searched through 2January 2020. Studies reporting the impact of IrAE on outcome in patients treated with antiprogrammed death receptor 1or PD-L1 were included. Twenty ninearticles were included. IrAEs were associated with improved outcomes with high heterogeneity. With a landmark approach, the association between IrAE and outcome remains significant but the effect size was smaller (hazard ratio0.61 vs 0.41 for overall survival;p=0.015; hazard ratio0.66 vs 0.47 for progression-free survival, p =0.029; odds ratio2.59 vs 6.77 for overall response rate;p<0.001), no significant heterogeneity. Our analysis suggests a confounding effect of immortal time bias and a real effect of IrAE on outcome.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
